Kura Oncology Management

Management criteria checks 3/4

Kura Oncology's CEO is Troy Wilson, appointed in Mar 2015, has a tenure of 9.58 years. total yearly compensation is $5.25M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth €9.60M. The average tenure of the management team and the board of directors is 3.9 years and 9 years respectively.

Key information

Troy Wilson

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage	12.3%
CEO tenure	9.6yrs
CEO ownership	0.8%
Management average tenure	3.9yrs
Board average tenure	9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Troy Wilson's remuneration changed compared to Kura Oncology's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$182m
Mar 31 2024	n/a	n/a	-US$168m
Dec 31 2023	US$5m	US$646k	-US$153m
Sep 30 2023	n/a	n/a	-US$143m
Jun 30 2023	n/a	n/a	-US$140m
Mar 31 2023	n/a	n/a	-US$137m
Dec 31 2022	US$5m	US$621k	-US$136m
Sep 30 2022	n/a	n/a	-US$135m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	n/a	n/a	-US$132m
Dec 31 2021	US$9m	US$600k	-US$130m
Sep 30 2021	n/a	n/a	-US$124m
Jun 30 2021	n/a	n/a	-US$114m
Mar 31 2021	n/a	n/a	-US$101m
Dec 31 2020	US$4m	US$573k	-US$90m
Sep 30 2020	n/a	n/a	-US$81m
Jun 30 2020	n/a	n/a	-US$74m
Mar 31 2020	n/a	n/a	-US$68m
Dec 31 2019	US$3m	US$542k	-US$63m
Sep 30 2019	n/a	n/a	-US$61m
Jun 30 2019	n/a	n/a	-US$60m
Mar 31 2019	n/a	n/a	-US$60m
Dec 31 2018	US$5m	US$526k	-US$60m
Sep 30 2018	n/a	n/a	-US$55m
Jun 30 2018	n/a	n/a	-US$49m
Mar 31 2018	n/a	n/a	-US$43m
Dec 31 2017	US$2m	US$472k	-US$35m

Compensation vs Market: Troy's total compensation ($USD5.25M) is above average for companies of similar size in the German market ($USD1.67M).

Compensation vs Earnings: Troy's compensation has been consistent with company performance over the past year.

CEO

Troy Wilson (55 yo)

9.6yrs

Tenure

US$5,251,407

Compensation

Dr. Troy Edward Wilson, Ph D., J.D., is Co-Founder of Avidity Biosciences Inc. and had been its Executive Chairman since February 2019 until January 2021 and serves as its Independent Chairman of the Board...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Troy Wilson	Chairman	9.6yrs	US$5.25m	0.76% $ 9.6m
Kathleen Ford	Chief Operating Officer	5.2yrs	US$2.16m	0.014% $ 176.4k
Teresa Bair	Chief Legal Officer & Corporate Secretary	3yrs	US$1.98m	0.0070% $ 89.2k
Stephen Dale	Chief Medical Officer	4.2yrs	US$2.47m	0.0039% $ 50.0k
Thomas Doyle	Senior Vice President of Finance & Accounting	2.7yrs	no data	0.015% $ 196.6k
Pete De Spain	Executive Vice President of Investor Relations & Corporate Communications	7yrs	no data	no data
Roger Bakale	Senior Vice President of Manufacturing & Supply Chain	4.8yrs	no data	no data
Maureen Clancy	VP and Global Head of Program Leadership & Project Management	3.6yrs	no data	no data
Mollie Leoni	Executive Vice President of Clinical Development	2.7yrs	no data	no data
Brian Powl	Chief Commercial Officer	1.2yrs	no data	no data
Francis Burrows	Senior Vice President of Translational Research	no data	no data	no data

3.9yrs

Average Tenure

53yo

Average Age

Experienced Management: KUR's management team is considered experienced (3.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Troy Wilson	Chairman	9.6yrs	US$5.25m	0.76% $ 9.6m
Daniel Von Hoff	Clinical Advisor	no data	no data	no data
Thomas Malley	Independent Director	9yrs	US$275.69k	0% $ 0
Mary Szela	Independent Director	5.9yrs	US$279.80k	0% $ 0
Faheem Hasnain	Lead Independent Director	9.5yrs	US$300.54k	0.031% $ 397.3k
Frank McCormick	Scientific Advisor	no data	no data	no data
Neal Rosen	Scientific Advisor	no data	no data	no data
Kevan Shokat	Chairman of the Scientific Advisory Board	no data	no data	no data
Alan Houghton	Clinical Advisor	no data	no data	no data
Josep Tabernero	Clinical Advisor	no data	no data	no data
Steven Horwitz	Clinical Advisor	no data	no data	no data
Carol Schafer	Independent Director	3.3yrs	US$279.05k	0% $ 0

9.0yrs

Average Tenure

63.5yo

Average Age

Experienced Board: KUR's board of directors are considered experienced (9 years average tenure).

Kura Oncology Management

Management criteria checks 3/4

Key information

Recent management updates

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Insufficient new directors

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Chief Medical Officer recently sold €56k worth of stock

Kura Oncology, Inc. Announces Executive Changes

Recent updates

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist)

Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Now 20% undervalued

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index

Insufficient new directors

New minor risk - Share price stability

Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc. to Report Q1, 2024 Results on May 02, 2024

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Now 21% undervalued

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

New major risk - Share price stability

Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC

Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million.

Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress

Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023

Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Chief Medical Officer recently sold €56k worth of stock

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib

Kura Oncology, Inc. announced that it expects to receive $150.000003 million in funding from Bristol-Myers Squibb Company,

Kura Oncology, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Kura Oncology, Inc. Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

Kura Oncology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Independent Director Robert Hoffman has left the company

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Index

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

New 90-day low: €22.00

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day low: €24.40

Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 At American Society of Hematology Annual Meeting

New 90-day high: €29.40

Kura Oncology, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Kura Oncology, Inc. Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Ka Inhibitor in Head and Neck Squamous Cell Carcinoma

New 90-day high: €26.40

Kura Oncology, Inc. to Report Q1, 2020 Results on May 04, 2020

New 90-day high: €24.80

New 90-day high - €18.50

New 90-day high - €17.50

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members